MRK Stock Analysis & Forecast (2026)

Merck & Co., Inc. Healthcare Drug Manufacturers - General
$119.07
Current Price
84%
Strong Buy
View Plans
Data refreshed: April 20, 2026

Key Financial Metrics

Market Cap
$294.39B
P/E Ratio (TTM)
16.4x
P/E Forward
12.2x
Revenue Growth
5.0%
Gross Margin
77.2%
Net Margin
28.1%
Return on Equity
36.9%
Debt/Equity
0.96

AI Analysis Summary

Merck & Co., Inc. (MRK) is a Healthcare company in the Drug Manufacturers - General industry with a 84% Strong Buy Score. Key strengths include Gross Margin (77.2%), Net Margin (28.1%), Return on Equity (36.9%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Moderate Gross Margin: Excellent Net Margin: Excellent Return on Equity: Excellent Debt/Equity: Elevated

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

MRK Fundamental Analysis Report
PDF Report Preview
84%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free MRK Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes MRK fundamentals to generate buy/sell signals and Strong Buy Scores.

Why MRK Has a 84% Score

Our AI evaluates Merck & Co., Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Strong Buy rating:

Recent Catalysts for MRK

Key developments and data points that may impact Merck & Co., Inc.'s trajectory:

Earnings declined -19.3% — watch for stabilization in coming quarters.
Wall Street consensus target is $129.81 (+9.0% from current price), based on 27 analyst estimates.
Analyst consensus recommendation: Buy.
Institutional ownership at 81.4% — strong smart-money backing.
Dividend yield of 2.86% provides income while you wait for capital appreciation.

MRK vs. Peers

How Merck & Co., Inc. stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
MRK $119.07 $294.39B 16.4x 5.0% 28.1% 36.9%
JNJ $234.18 $564.35B 21.2x 9.9% 21.8%
UNH $324.63 $294.66B 24.5x 12.3% 2.7% 12.5%
PFE $27.56 $156.77B 20.3x -1.2% 12.4% 8.9%
ABBV $208.38 $368.57B 87.6x 10.0% 6.9% 6225.0%

Main Risks for MRK Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Merck & Co., Inc.:

Low beta of 0.28 suggests limited upside participation in bull markets.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

MRK Balance Sheet & Cash Flow

A snapshot of Merck & Co., Inc.'s financial health based on the most recent filings:

Total Cash
$14.57B
Total Debt
$50.53B
Current Ratio
1.54
FCF Yield
4.0%
EBITDA
$29.11B
Operating Margin
32.8%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

MRK Valuation Snapshot

Trailing P/E
16.4x
Fairly valued
Forward P/E
12.2x
Earnings growth expected
Price / Book
5.6x
Premium
PEG Ratio
3.64
Expensive vs growth
Analyst Target (Mean)
$129.81
Range: $100 – $150
Dividend Yield
2.86%
5Y avg: 3.03%
52-Week Price Range — MRK is trading at 88% of its range
$73.31 (52W Low) $125.14 (52W High)

Is MRK a Buy Right Now?

Based on our AI-powered fundamental analysis, MRK has a Strong Buy Score of 84%, earning a "Strong Buy" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Strong Buy Signal

Merck & Co., Inc. demonstrates robust fundamentals across multiple categories. Key strengths include Gross Margin (77.2%) and Net Margin (28.1%). The stock shows characteristics typically associated with outperformers.

MRK AI Buy & Sell Signals Explained

Our AI analyzes Merck & Co., Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 84% score:

  • Revenue Growth: 5.0% year-over-year (positive)
  • Gross Margin: 77.2% (strong pricing power)
  • Net Margin: 28.1% (highly profitable)
  • Return on Equity: 36.9% (excellent capital efficiency)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for MRK on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With MRK currently trading at $119.07, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when MRK reaches key technical levels.

Earnings & Revenue Outlook

Merck & Co., Inc. operates in the Healthcare sector, specifically in Drug Manufacturers - General. Understanding earnings trends is crucial for forecasting MRK's trajectory.

Current revenue growth of 5.0% slightly beats the average company.

Visit our Earnings Calendar to track upcoming MRK earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

MRK Stock Forecast (Next 3–12 Months)

Our AI projects MRK's trajectory based on current fundamentals and historical patterns. With a 84% Strong Buy Score, here's what the data suggests:

Bullish Outlook: Merck & Co., Inc. shows strong fundamental momentum. Net margins of 28.1% indicate pricing power and operational efficiency. Stocks with similar profiles have historically outperformed over 12-month periods.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if MRK is fairly priced. Here's the current snapshot:

  • Market Capitalization: $294.39B
  • P/E Ratio (TTM): 16.4x (fairly valued)
  • Forward P/E: 12.2x (based on analyst estimates)
  • Debt/Equity: 0.96 (moderate leverage)

Our AI weighs these metrics against growth rates and margin quality to determine if MRK offers compelling risk-adjusted returns at current prices.

Bull Case for MRK

Here's why investors are bullish on Merck & Co., Inc.:

  • Gross Margin (77.2%)
  • Net Margin (28.1%)
  • Return on Equity (36.9%)

With a 84% Strong Buy Score, the bull case is well-supported by current fundamentals. The stock exhibits characteristics of quality compounders that tend to outperform long-term.

Bear Case & Risks for MRK

Every investment carries risk. Here are potential concerns for MRK investors:

  • Competitive pressures in Healthcare
  • Macroeconomic sensitivity and interest rate exposure
  • Execution risk on growth initiatives
  • Valuation compression if growth slows

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

MRK Summary: Merck & Co., Inc. earns a 84% Strong Buy Score based on AI analysis of fundamental data. Trading at $119.07 with a $294.39B market cap, the stock shows strong fundamentals supporting a bullish 12-month outlook.

Bull Case: Gross Margin (77.2%), Net Margin (28.1%)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free MRK PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this MRK analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like MRK.

What Are Demand Zones?

Find key support and resistance levels for MRK and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for MRK

Demand Zone Analyzer MRK Live Chart Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

Frequently Asked Questions about MRK

Is MRK a good buy right now?
MRK currently has a Strong Buy Score of 84% (Strong Buy). Based on AI analysis of fundamentals, MRK shows strong buy signals with solid revenue growth, margins, and return metrics. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the MRK stock forecast for 2026?
Our AI forecasts MRK based on current fundamentals: revenue growth of 5.0%, net margin of 28.1%, and P/E of 16.4x. The 84% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for MRK?
View real-time MRK demand zones (support) and supply zones (resistance) on our Demand Zones page. With MRK currently at $119.07, you can see how close the stock is to key technical levels. Subscribe to get alerts when MRK approaches these zones.
How do MRK fundamentals compare to peers?
Merck & Co., Inc. operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 77.2%, ROE 36.9%, Debt/Equity 0.96. The 84% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the MRK analysis PDF report free?
Yes! Your first MRK fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Merck & Co., Inc.'s market cap and P/E ratio?
Merck & Co., Inc. (MRK) has a market cap of $294.39B and a trailing P/E ratio of 16.4x (forward P/E: 12.2x). These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This MRK analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.